NCT05404763

Mepolizumab and Physical Activity in Severe Asthma

Evolution of Physical Activity in Severe Asthmatic Patients Treated With Mepolizumab

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 102 (estimated)
• Sponsor: University Hospital, Lille · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Severe asthma is a debilitating condition associated with frequent symptoms, life-threatening exacerbations and corticosteroid side-effects. Exercise limitation due to exercise-induced bronchoconstriction, dynamic lung hyperinflation and comorbidity may be a strong determinant of the disease burden. Mepolizumab is a monoclonal anti-interleukin-5 (IL-5) antibody that reduces the rate of severe exacerbations, asthma symptoms and oral glucocorticoid requirement, and improves quality of life and work productivity in severe eosinophilic asthma. However, its impact on physical activity and exercise tolerance is unknown. We hypothesize that a 6-month treatment with mepolizumab is associated with an improvement in daily life physical activity and exercise tolerance in relation with enhanced ventilatory mechanics.

Conditions

• Asthma
• Asthma; Eosinophilic

Timeline

• Start date: 2023-02-02
• Primary completion: 2025-02-02
• Completion: 2025-07-02
• First posted: 2022-06-03
• Last updated: 2024-05-23

Locations

1 site across 1 country: France